XML 39 R23.htm IDEA: XBRL DOCUMENT v3.3.1.900
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2015
Summary of Significant Accounting Policies  
Schedule of receivables from maximum payments from collaborative partners and licensees

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Potential Milestones (in millions)

 

 

    

 

 

    

 

 

    

 

 

    

Total

 

Partner

 

Development-based

 

Regulatory-based

 

Sales-based

 

Milestones

 

Alexion (1)

 

$

51.0

 

$

168.0

 

$

180.0

 

$

399.0

 

Amgen

 

 

232.5

 

 

345.0

 

 

1,080.0

 

 

1,657.5

 

BI

 

 

9.0

 

 

6.0

 

 

12.0

 

 

27.0

 

CSL 2009 (1)

 

 

6.0

 

 

4.0

 

 

5.0

 

 

15.0

 

Janssen (1)

 

 

6.0

 

 

 —

 

 

4.0

 

 

10.0

 

Merck (1)

 

 

3.5

 

 

6.0

 

 

 

 

9.5

 

MorphoSys (1)

 

 

62.0

 

 

187.0

 

 

50.0

 

 

299.0

 

Novo Nordisk (2)

 

 

36.3

 

 

51.0

 

 

80.0

 

 

167.3

 

Total

 

$

406.3

 

$

767.0

 

$

1,411.0

 

$

2,584.3

 


(1)

The payments are solely dependent upon activities of the collaborative partner or licensee.

Xencor provides research services under the agreement with Novo Nordisk

Schedule of revenue by licensees

The $27.8 million, $9.5 million and $10.2 million of revenue recorded for the years ended December 31, 2015, 2014 and 2013, respectively was earned principally from the following licensees (in millions):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended

 

 

 

December 31, 

 

 

 

2015

 

2014

 

2013

 

Amgen

    

$

13.8

    

$

6.9

    

$

2.2

 

Alexion

 

 

8.5

 

 

1.0

 

 

0.9

 

Novo Nordisk

 

 

2.9

 

 

 —

 

 

 —

 

CSL

 

 

2.5

 

 

0.7

 

 

2.9

 

MorphoSys

 

 

 

 

 

 

3.0

 

Merck

 

 

0.1

 

 

0.6

 

 

1.0

 

Other

 

 

 —

 

 

0.3

 

 

0.2

 

Total

 

$

27.8

 

$

9.5

 

$

10.2

 

 

Schedule of revenue from U.S. and Non U.S. sources

A breakdown of our revenue from U.S. and Non‑U.S. sources for the years ended December 31, 2015, 2014 and 2013 is as follows (in millions):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended

 

 

 

December 31, 

 

 

 

2015

 

2014

 

2013

 

U.S. Revenue

    

$

22.4

    

$

8.6

    

$

4.2

 

Non-U.S. Revenue

 

 

5.4

 

 

0.9

 

 

6.0

 

Total

 

$

27.8

 

$

9.5

 

$

10.2

 

 

Schedule of assets recorded at fair value

The Company measures the fair value of financial assets using the highest level of inputs that are reasonably available as of the measurement date. The assets recorded at fair value are classified within the hierarchy as follows for the periods reported (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2015

 

    

Total

    

    

 

 

 

 

 

 

Fair Value

 

Level 1

 

Level 2

 

 

 

 

 

 

 

 

 

 

Money Market Funds in Cash and Cash Equivalents

 

$

9,453

 

$

9,453

 

$

 —

Corporate Securities

 

 

114,846

 

 

 —

 

 

114,846

Government Securities

 

 

65,885

 

 

 —

 

 

65,885

 

 

$

190,184

 

$

9,453

 

$

180,731

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2014

 

    

Total

    

    

 

 

 

 

 

 

Fair Value

 

Level 1

 

Level 2

 

 

 

 

 

 

 

 

 

 

Money Market Funds in Cash and Cash Equivalents

 

$

54,429

 

$

54,429

 

$

 —

Corporate Securities

 

 

 —

 

 

 —

 

 

 —

Government Securities

 

 

 —

 

 

 —

 

 

 —

 

 

$

54,429

 

$

54,429

 

$

 —

 

Schedule of useful lives by asset category

 

 

 

 

 

    

    

 

Computers, software and equipment

 

3 - 5 years

 

Furniture and fixtures

 

5 - 7 years

 

Leasehold improvements

 

5 - 7 years or remaining

 

 

 

lease term, whichever is less

 

 

Schedule of carrying amount and accumulated amortization of patents, licenses, and other intangibles

The carrying amount and accumulated amortization of patents, licenses, and other intangibles is as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

December 31,

 

 

 

2015

 

2014

 

Patents, definite life

    

$

6,488

    

$

5,720

 

Patents, pending issuance

 

 

4,051

 

 

3,654

 

Licenses and other amortizable intangible assets

 

 

2,072

 

 

1,797

 

Nonamortizable intangible assets (trademarks)

 

 

399

 

 

400

 

Total gross carrying amount

 

 

13,010

 

 

11,571

 

Accumulated amortization—patents

 

 

(2,214)

 

 

(1,776)

 

Accumulated amortization—licenses and other

 

 

(825)

 

 

(679)

 

Total intangible assets, net

 

$

9,971

 

$

9,116

 

 

Future amortization expense for patents, licenses, and other intangible assets

 

 

 

 

 

 

    

Year ended

 

 

 

December 31, 

 

 

 

(in thousands)

 

2016

 

$

636

 

2017

 

 

639

 

2018

 

 

628

 

2019

 

 

616

 

2020

 

 

609

 

Thereafter

 

 

2,393

 

Total

 

$

5,521

 

 

Schedule of potentially dilutive securites

 

 

 

 

 

 

 

 

 

 

Year Ended

 

 

 

December 31, 

 

 

 

2015

 

2014

 

2013

 

 

 

(in thousands)

 

Options to purchase common stock

 

1,281

 

2,827

 

1,794

 

Employee stock purchase plan shares

 

75

 

25

 

 

Total

 

1,356

 

2,852

 

1,794

 

 

Schedule of basic and diluted net loss per common share

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended December 31, 

 

 

 

2015

 

2014

 

2013

 

 

 

(in thousands, except

 

 

 

per share data)

 

Basic

    

 

    

    

 

    

    

 

    

 

Numerator:

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(17,592)

 

$

(16,422)

 

$

(60,259)

 

Deemed contribution

 

 

 

 

 

 

144,765

 

Net income (loss) attributable to common stockholders for basic net income (loss) per share

 

$

(17,592)

 

$

(16,422)

 

$

84,506

 

Denominator:

 

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding

 

 

39,015,131

 

 

31,390,631

 

 

2,472,581

 

Basic net income (loss) per common share

 

$

(0.45)

 

$

(0.52)

 

$

34.18

 

Diluted:

 

 

 

 

 

 

 

 

 

 

Numerator:

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to common stockholders for basic net income (loss) per share

 

$

(17,592)

 

$

(16,422)

 

$

84,506

 

Deemed contribution

 

 

 

 

 

 

(144,765)

 

Net loss attributable to common stockholders for diluted net loss per share

 

$

(17,592)

 

$

(16,422)

 

$

(60,259)

 

Denominator:

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding used in computing basic net loss per common share

 

 

39,015,131

 

 

31,390,631

 

 

2,472,581

 

Dilutive effect of conversion of convertible preferred stock

 

 

 

 

 

 

13,173,208

 

Weighted-average number of common shares outstanding used in computing net loss per common share

 

 

39,015,131

 

 

31,390,631

 

 

15,645,789

 

Diluted net loss per common share

 

$

(0.45)

 

$

(0.52)

 

$

(3.85)